Novel Cholesterol Drugs Move Forward In Clinical Trials

–New information about upcoming cholesterol drugs from the Medicines Company and Esperion Recently the makers of two novel cholesterol-lowering drugs in development provided important updates on their progress. On Tuesday, the Medicines Company announced positive top-line results for a trial of its unusual PCSK9 synthesis inhibitor scheduled to be presented in November. Last week Esperion...Click here to continue reading...

Source: CardioBrief - October 18, 2016 Category: Cardiology Authors: Larry Husten Tags: Policy & Ethics Prevention, Epidemiology & Outcomes bempedoic acid cholesterol Esperion ETC-1002 FDA Medicines Company PCSK9si Source Type: blogs